Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS10BR05 in Multiple System Atrophy
NCT03265444Phase 1Completed
- Sponsor
- Corestemchemon
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CS10BR05 in multiple system atrophy (MSA), sponsored by Corestemchemon. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Apr 2018; status: completed.
02
Drugs
CS10BR05
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT03265444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03265444.